ACADIA Pharmaceuticals Inc. (ACAD) Market Cap & Valuation Ratios
ACADIA Pharmaceuticals Inc. (ACAD) has a market cap of $3.4B, a trailing P/E of 8.8 and a price-to-sales ratio of 3.0, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACADACADIA Pharmaceuticals Inc.Follow ACAD — free
—
Price chart with a free account
- Market cap
- 3.4B
- P/E TTM
- 8.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ACAD | 3.4 | 8.8 | 2.1 | 25.1 | 4.3% | +12% | 8% | 9% |
| RLAY | 4.0 | — | 373.2 | — | -5.3% | +24% | — | -47% |
| TNGX | 3.9 | — | 54.3 | — | -3.7% | +121% | -253% | -35% |
| ARQT | 3.9 | 148.6 | 8.2 | 103.9 | 1.0% | +76% | 7% | 14% |
| XENE | 3.4 | — | — | — | -9.9% | — | — | -54% |
| IDYA | 3.3 | — | 10.8 | — | -3.4% | +3024% | -93% | -24% |
| CELC | 3.2 | — | — | — | -6.0% | — | — | — |
| ELVN | 3.0 | — | — | — | -2.2% | — | — | -22% |
| TARS | 3.0 | — | 4.3 | — | 1.9% | +105% | -8% | -19% |
| DNLI | 2.9 | — | 619.4 | — | -14.9% | — | — | -71% |
| DYN | 2.9 | — | — | — | — | — | — | -262% |
| Median of these 10 | 148.6 | 32.5 | 103.9 | -3.7% | +105% | -50% | -35% |
P/E 8.8 vs. a peer median of 148.6; EV/Sales 2.1 vs. 32.5. ACAD's own P/E sits at the 0th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesACADIA Pharmaceuticals Inc. — questions
- What is ACADIA Pharmaceuticals Inc.'s market cap?
- $3.4B.
- What is ACADIA Pharmaceuticals Inc.'s P/E ratio?
- 8.8 on trailing twelve-month earnings to 2026-06-30.
- What is ACADIA Pharmaceuticals Inc.'s price-to-sales ratio?
- 3.0.
Every figure on this page comes from ACADIA Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.